Journal ArticleDOI
Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial
Letizia Mazzini,Ivana Ferrero,Ivana Ferrero,V. Luparello,Deborah Rustichelli,Monica Gunetti,Katia Mareschi,Katia Mareschi,Lucia Testa,Alessandro Stecco,R. Tarletti,Massimo Miglioretti,E. Fava,N. Nasuelli,Carlo Cisari,Maurilio Massara,R. Vercelli,G.D. Oggioni,Alessandro Carriero,Roberto Cantello,Francesco Monaco,Franca Fagioli +21 more
Reads0
Chats0
TLDR
This study confirms that M SC transplantation into the spinal cord of ALS patients is safe and that MSCs might have a clinical use for future ALS cell based clinical trials.About:
This article is published in Experimental Neurology.The article was published on 2010-05-01. It has received 369 citations till now. The article focuses on the topics: Transplantation & Clinical trial.read more
Citations
More filters
Journal ArticleDOI
Clinical Trials with Mesenchymal Stem Cells: An Update:
TL;DR: Clinical trials using MSCs for representative diseases, including hematological disease, graft-versus-host disease, organ transplantation, diabetes, inflammatory diseases, and diseases in the liver, kidney, and lung are analyzed, as well as cardiovascular, bone and cartilage, neurological, and autoimmune diseases.
Journal ArticleDOI
Stem Cell Therapies in Clinical Trials: Progress and Challenges
TL;DR: Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of conditions using a variety of stem cell types and applications are progressing in trials, some with early benefits to patients.
Journal ArticleDOI
EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) : revised report of an EFNS task force
Peter M. Andersen,Sharon Abrahams,Gian Domenico Borasio,Mamede de Carvalho,Adriano Chiò,Philip Van Damme,Orla Hardiman,Katja Kollewe,Karen E. Morrison,Susanne Petri,Pierre-François Pradat,Vincenzo Silani,Barbara Tomik,Maria Wasner,Markus Weber +14 more
TL;DR: The evidence base for the diagnosis and management of amyotrophic lateral sclerosis (ALS) is weak and needs to be strengthened, according to the authors.
Journal ArticleDOI
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Dimitrios Karussis,Clementine Karageorgiou,Adi Vaknin-Dembinsky,Basan Gowda-Kurkalli,John M. Gomori,Ibrahim Kassis,Jeff W.M. Bulte,Panayiota Petrou,Tamir Ben-Hur,Oded Abramsky,Shimon Slavin +10 more
TL;DR: Transplantation of MSCs in patients with MS and ALS is a clinically feasible and relatively safe procedure and induces immediate immunomodulatory effects.
Journal ArticleDOI
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Jianming Tan,Weizhen Wu,Xiumin Xu,Lianming Liao,Feng Zheng,Shari Messinger,Xinhui Sun,Jin Chen,Shunliang Yang,Jinquan Cai,Xia Gao,Antonello Pileggi,Camillo Ricordi +12 more
TL;DR: Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year.
References
More filters
Journal ArticleDOI
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Massimo Dominici,K. Le Blanc,Ingo Mueller,I. Slaper-Cortenbach,Frank C. Marini,Diane S. Krause,Robert J. Deans,Armand Keating,Darwin J. Prockop,Edwin M. Horwitz +9 more
TL;DR: The Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC, believing this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.
Journal ArticleDOI
El Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis
TL;DR: The criteria described below represent the result of a three-day workshop, convened at Airlie Conference Center, Warrenton, Virginia on 2–4 April, 1998 by the World Federation of Neurology Research Committee on Motor Neuron Diseases, and are placed on the WFN ALS website.
Journal ArticleDOI
Mesenchymal stem cells in health and disease
TL;DR: The targets and mechanisms of M SC-mediated immunomodulation and the possible translation of MSCs to new therapeutic approaches are discussed.
Journal ArticleDOI
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Séverine Boillée,Koji Yamanaka,Christian S. Lobsiger,Neal G. Copeland,Nancy A. Jenkins,George Kassiotis,George Kollias,Don W. Cleveland +7 more
TL;DR: Onset and progression of amyotrophic lateral sclerosis represent distinct disease phases defined by mutant action within different cell types to generate non–cell-autonomous killing of motor neurons; these findings validate therapies, including cell replacement, targeted to the non-neuronal cells.
Journal ArticleDOI
Gastric cancer originating from bone marrow-derived cells.
JeanMarie Houghton,Calin Stoicov,Sachiyo Nomura,Sachiyo Nomura,Arlin B. Rogers,Jane E. Carlson,Hanchen Li,Xun Cai,James G. Fox,James R. Goldenring,James R. Goldenring,Timothy C. Wang +11 more
TL;DR: It is shown that although acute injury, acute inflammation, or transient parietal cell loss within the stomach do not lead to BMDC recruitment, chronic infection of C57BL/6 mice with Helicobacter induces repopulation of the stomach with BMDCs, suggesting that epithelial cancers can originate from marrow-derived sources and thus have broad implications for the multistep model of cancer progression.